Clinical Trial: Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07894367) titled 'Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study' on Sept. 28.

Brief Summary: Research objective: To evaluate the efficacy and safety of gematinib combined with lenvatinib in the treatment of advanced or metastatic NSCLC with MET overexpression that has failed standard therapy Experimental design: Prospective, multicenter, single-arm Study population: Patients with locally advanced or metastatic NSCLC who have overexpression of the MET protein (IHC 3+: >= 50% of tumor cells show strong...